Thermo Fisher Scientific is expanding its oral solid dose (OSD) footprint with a $22-million total investment since 2021 in its Cincinnati, OH, and Bend, OR sites. Together, these expansions aim to enable R&D, manufacturing and testing of OSD drug formulations – doubling the Bend site’s existing footprint and continuing a multi-year investment plan in Cincinnati – to bolster capabilities across the company’s global CDMO and CRO network. 
 
Today, OSD make up 84% of all medications on the market. To help meet the increasing demand for small molecule OSD solutions, Cincinnati adds dedicated flexible R&D space, supporting pre-clinical early development of OSD formulations through rapid project initiation and the use of next-generation technologies for data-informed decision-making.  
 
The Bend expansion is focused on R&D manufacturing and testing, including bench and pilot scale spray drying, hot-melt extrusion and dry granulation. These additions to the site bolster capabilities at the company’s center of excellence for early development and advanced drug delivery, including solubility and bioavailability enhancement solutions and digital modeling. These capabilities aim to address some of the largest challenges for pharma and biotech customers to help accelerate pre-clinical oral drug product development and reduce timelines to GMP production of clinical trial materials.  

“With more than 30 years of expertise in the space, Thermo Fisher’s OSD teams are dedicated to ensuring customers know what lies ahead by providing unparalleled insights into needs that span from navigating the regulatory landscape to overcoming potential formulation challenges,” said Michelle Logan, vice president and general manager, drug product North America, Thermo Fisher Scientific. “Expanding our capabilities in North America builds services in OSD formulations to help ensure that our customers can develop and commercialize accessible, life-saving therapies.”